Novel Therapeutic Targets

  • John Farley
  • Michael J. BirrerEmail author
Part of the Cancer Treatment and Research book series (CTAR, volume 149)


Ovarian cancer remains an important health problem for women in the United States. It is estimated that there will be 21,650 cases of invasive ovarian cancer resulting in 15,520 deaths in 2008.1 Ovarian cancer has the highest case fatality rate of any gynecologic cancer,1 and it is the most common cause of death from cancers of the female genital tract.1, 2, 3 The high case fatality rate results from the frequent diagnosis of epithelial ovarian cancer at an advanced stage: 75% of all cases are diagnosed as stage III or IV, where the disease has spread throughout the abdomen.1,4,5Patients with advanced-stage disease have a 5-year survival of only 29%. Despite years of clinical trials, there is a only a limited number of chemotherapeutic agents with activity against epithelial ovarian cancer. Further, all patients with this disease (regardless of histology and tumor grade) are treated up-front in the same fashion with the standard of the combination of platinum and...


Vascular Endothelial Growth Factor Ovarian Cancer Epidermal Growth Factor Receptor Chronic Myeloid Leukemia Epithelial Ovarian Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.PubMedGoogle Scholar
  2. 2.
    Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol. 2006;107:1399–1410.PubMedGoogle Scholar
  3. 3.
    Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–2529.PubMedGoogle Scholar
  4. 4.
    Piccart MJ, Bertelsen K, Stuart G, et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer. 2003;13(Suppl 2):144–148.PubMedGoogle Scholar
  5. 5.
    Tummala MK, McGuire WP. Recurrent ovarian cancer. Clin Adv Hematol Oncol. 2005;3:723–736.PubMedGoogle Scholar
  6. 6.
    Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002;20:1692–1703.PubMedGoogle Scholar
  7. 7.
    Demetri GD. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol. 2001;28:19–26.PubMedGoogle Scholar
  8. 8.
    Mauro MJ, Druker BJ. STI571: targeting BCR-ABL as therapy for CML. Oncologist. 2001;6:233–238.PubMedGoogle Scholar
  9. 9.
    Bookman MA. Biologic therapies for gynecologic cancer. Curr Opin Oncol. 1995;7:478–484.PubMedGoogle Scholar
  10. 10.
    Bookman MA. Biological therapy of ovarian cancer: current directions. Semin Oncol. 1998;25:381–396.PubMedGoogle Scholar
  11. 11.
    Darcy KM, Schilder RJ. Relevant molecular markers and targets. Gynecol Oncol. 2006;103:S6--S13.PubMedGoogle Scholar
  12. 12.
    Goel S, Mani S, Perez-Soler R. Tyrosine kinase inhibitors: a clinical perspective. Curr Oncol Rep. 2002;4:9–19.PubMedGoogle Scholar
  13. 13.
    Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757–1763.PubMedGoogle Scholar
  14. 14.
    Aguilar Z, Akita RW, Finn RS, et al. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene. 1999;18:6050–6062.PubMedGoogle Scholar
  15. 15.
    Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999;18:2241–2251.PubMedGoogle Scholar
  16. 16.
    Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol 2007;25:2894–2901.PubMedGoogle Scholar
  17. 17.
    Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000;60:203–212.PubMedGoogle Scholar
  18. 18.
    Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–364.PubMedGoogle Scholar
  19. 19.
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.PubMedGoogle Scholar
  20. 20.
    Abulafia O, Triest WE, Sherer DM. Angiogenesis in malignancies of the female genital tract. Gynecol Oncol. 1999;72:220–231.PubMedGoogle Scholar
  21. 21.
    Paley PJ, Staskus KA, Gebhard K, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer. 1997;80:98–106.PubMedGoogle Scholar
  22. 22.
    Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149–153.PubMedGoogle Scholar
  23. 23.
    Li CY, Shan S, Huang Q, et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst. 2000;92:143–147.PubMedGoogle Scholar
  24. 24.
    Verhoef C, de Wilt JH, Verheul HM. Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology. Curr Pharm Des. 2006;12:2623–2630.PubMedGoogle Scholar
  25. 25.
    Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res. 2000;60:2190–2196.PubMedGoogle Scholar
  26. 26.
    Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–1544.PubMedGoogle Scholar
  27. 27.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342.PubMedGoogle Scholar
  28. 28.
    Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:5165–5171.PubMedGoogle Scholar
  29. 29.
    Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol. 2006;102:140–144.PubMedGoogle Scholar
  30. 30.
    Chura JC, Van Iseghem K, Downs LS Jr, Carson LF, Judson PL. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol. 2007;107:326–330.PubMedGoogle Scholar
  31. 31.
    Arora N, Tewari D, Cowan C, Saffari B, Monk BJ, Burger RA. Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma. Int J Gynecol Cancer. 2008;18:369–372.PubMedGoogle Scholar
  32. 32.
    Agus DB, Bunn PA Jr, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol. 2000;27:53–63; discussion 92–100.PubMedGoogle Scholar
  33. 33.
    Christensen JG, Schreck RE, Chan E, et al. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res. 2001;7:4230–4238.PubMedGoogle Scholar
  34. 34.
    Cuello M, Ettenberg SA, Clark AS, et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001;61:4892–4900.PubMedGoogle Scholar
  35. 35.
    Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA Jr. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol. 2002;29:3–14.PubMedGoogle Scholar
  36. 36.
    Kumar R, Mandal M, Vadlamudi R. New insights into anti-HER-2 receptor monoclonal antibody research. Semin Oncol. 2000;27:84–91; discussion 2–100.PubMedGoogle Scholar
  37. 37.
    Lei W, Mayotte JE, Levitt ML. EGF-dependent and independent programmed cell death pathways in NCI-H596 nonsmall cell lung cancer cells. Biochem Biophys Res Commun. 1998;245:939–945.PubMedGoogle Scholar
  38. 38.
    Leu CM, Chang C, Hu C. Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. Oncogene. 2000;19:1665–1675.PubMedGoogle Scholar
  39. 39.
    Arteaga CL, Khuri F, Krystal G, Sebti S. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Semin Oncol. 2002;29:15–26.PubMedGoogle Scholar
  40. 40.
    Hackel PO, Zwick E, Prenzel N, Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol. 1999;11:184–189.PubMedGoogle Scholar
  41. 41.
    Hunter T. Signaling -- 2000 and beyond. Cell. 2000;100:113–127.PubMedGoogle Scholar
  42. 42.
    Riese DJ 2nd, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays. 1998;20:41–48.PubMedGoogle Scholar
  43. 43.
    Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–137.PubMedGoogle Scholar
  44. 44.
    Gullick WJ, Marsden JJ, Whittle N, Ward B, Bobrow L, Waterfield MD. Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res. 1986;46:285–292.PubMedGoogle Scholar
  45. 45.
    Scoccia B, Lee YM, Niederberger C, Ilekis JV. Expression of the ErbB family of receptors in ovarian cancer. J Soc Gynecol Invest. 1998;5:161–165.Google Scholar
  46. 46.
    Goff BA, Shy K, Greer BE, Muntz HG, Skelly M, Gown AM. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer. Eur J Gynaecol Oncol. 1996;17:487–492.PubMedGoogle Scholar
  47. 47.
    Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem. 1994;269:27595–27602.PubMedGoogle Scholar
  48. 48.
    Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 1997;3:2703–2707.PubMedGoogle Scholar
  49. 49.
    Divgi CR, Welt S, Kris M, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst. 1991;83:97–104.PubMedGoogle Scholar
  50. 50.
    Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:283–290.PubMedGoogle Scholar
  51. 51.
    Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648.PubMedGoogle Scholar
  52. 52.
    Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, Candelaria M, De la Garza-Salazar J. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev. 2006;32:180–190.PubMedGoogle Scholar
  53. 53.
    Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res. 2006;12:4441s--4445s.PubMedGoogle Scholar
  54. 54.
    Seiden MV, Burris HA, Matulonis U, et al. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol. 2007;104:727–731.PubMedGoogle Scholar
  55. 55.
    Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006;24:4324–4332.PubMedGoogle Scholar
  56. 56.
    Al-Obeidi FA, Lam KS. Development of inhibitors for protein tyrosine kinases. Oncogene. 2000;19:5690–5701.PubMedGoogle Scholar
  57. 57.
    Baselga J, Averbuch SD. ZD1839 ('Iressa') as an anticancer agent. Drugs. 2000;60(Suppl 1):33–40; discussion 1–2.PubMedGoogle Scholar
  58. 58.
    Bianco C, Bianco R, Tortora G, et al. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res. 2000;6:4343–4350.PubMedGoogle Scholar
  59. 59.
    Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res. 1999;5:909–916.PubMedGoogle Scholar
  60. 60.
    Sewell JM, Macleod KG, Ritchie A, Smyth JF, Langdon SP. Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). Br J Cancer. 2002;86:456–462.PubMedGoogle Scholar
  61. 61.
    Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res. 2005;11:5539–5548.PubMedGoogle Scholar
  62. 62.
    Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer. 2005;15:785–792.PubMedGoogle Scholar
  63. 63.
    Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA. 2005;102:7665–7670.PubMedGoogle Scholar
  64. 64.
    Campos S, Hamid O, Seiden MV, et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol. 2005;23:5597–5604.PubMedGoogle Scholar
  65. 65.
    Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 2002;7(Suppl 4):31–39.PubMedGoogle Scholar
  66. 66.
    Druker BJ. David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. J Clin Oncol. 2003;21:239s--245s.PubMedGoogle Scholar
  67. 67.
    Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res. 1994;54:3049–3053.PubMedGoogle Scholar
  68. 68.
    Alberts DS, Liu PY, Wilczynski SP, et al. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer. 2007;17:784–788.PubMedGoogle Scholar
  69. 69.
    Teneriello MG, Ebina M, Linnoila RI, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 1993;53:3103–3108.PubMedGoogle Scholar
  70. 70.
    Annunziata CM, Azad N, Hoskins E, Kohn EC. Tumor angiogenesis and metastasis. In: Hoskins WJ YRC, Markman M, Perez CA, Barakat R, Randall M, eds. Principles and Practice of Gynecologic Oncology. Philadelphia: Lippincott Williams & Wilkins: In press.Google Scholar
  71. 71.
    Alonio LV, Picconi MA, Dalbert D, et al. Ha-ras oncogene mutation associated to progression of papillomavirus induced lesions of uterine cervix. J Clin Virol. 2003;27:263–269.PubMedGoogle Scholar
  72. 72.
    Sun J, Blaskovich MA, Knowles D, et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res. 1999;59:4919–4926.PubMedGoogle Scholar
  73. 73.
    Hutson TE. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a phase III overview. Expert Rev Anticancer Ther. 2007;7:1193–1202.PubMedGoogle Scholar
  74. 74.
    Gao N, Flynn DC, Zhang Z, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol. 2004;287:C281--C291.PubMedGoogle Scholar
  75. 75.
    Dancey JE. Therapeutic targets: mTOR and related pathways. Cancer Biol Ther. 2006;5:1065–1073.PubMedGoogle Scholar
  76. 76.
    Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 2007;13:4261–4270.PubMedGoogle Scholar
  77. 77.
    Giavazzi R, Garofalo A, Ferri C, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res. 1998;4:985–992.PubMedGoogle Scholar
  78. 78.
    Brown PD. Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul. 1995;35:293–301.PubMedGoogle Scholar
  79. 79.
    Formenti S, Felix J, Salonga D, Danenberg K, Pike MC, Danenberg P. Expression of metastases-associated genes in cervical cancers resected in the proliferative and secretory phases of the menstrual cycle. Clin Cancer Res. 2000;6:4653–4657.PubMedGoogle Scholar
  80. 80.
    Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93:178–193.PubMedGoogle Scholar
  81. 81.
    Nguyen DM, Lorang D, Chen GA, Stewart JHt, Tabibi E, Schrump DS. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg. 2001;72:371–378; discussion 8–9.PubMedGoogle Scholar
  82. 82.
    An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 2000;11:355–360.PubMedGoogle Scholar
  83. 83.
    Nanbu K, Konishi I, Mandai M, et al. Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Cancer Detect Prev. 1998;22:549–555.PubMedGoogle Scholar
  84. 84.
    Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs. 1999;17:361–373.PubMedGoogle Scholar
  85. 85.
    Yoshida H, Kitamura K, Tanaka K, et al. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res. 1996;56:2945–2948.PubMedGoogle Scholar
  86. 86.
    Cheson BD. Hematologic malignancies: new developments and future treatments. Semin Oncol. 2002;29:33–45.PubMedGoogle Scholar
  87. 87.
    Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001;7:1419–1428.PubMedGoogle Scholar
  88. 88.
    Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol. 2005;23:5943–5949.PubMedGoogle Scholar
  89. 89.
    Ramirez PT, Landen CN Jr, Coleman RL, et al. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecol Oncol. 2008;108:68–71.PubMedGoogle Scholar
  90. 90.
    Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1999;5:810–816.PubMedGoogle Scholar
  91. 91.
    MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem. 2000;275:38953–38956.PubMedGoogle Scholar
  92. 92.
    Manzano RG, Montuenga LM, Dayton M, et al. CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene. 2002;21:4435–4447.PubMedGoogle Scholar
  93. 93.
    Hayakawa J, Ohmichi M, Kurachi H, et al. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 2000;60:5988–5994.PubMedGoogle Scholar
  94. 94.
    Friday BYC, Sminth P, Adejei A. A potential role for the modulation of a negative feedback loop between Erk and Raf mediating sensitivity to the MEK inhibitor AZD6244 (ARRY-142886) in human lung cancer cell lines. Proc Am Assoc Cancer Res. 2006;47:A4868.Google Scholar
  95. 95.
    Tran ESK, Chow P, Huynh H. Targeted inhibition of the MEK-ERK signaling cascade by the selective MEK 1/2 inhibitor AZD6244 (ARRAY-142886) for the treatment of hepatocellular carcinoma. Proc Am Assoc Cancer Res. 2006;47:A5470.Google Scholar
  96. 96.
    Morgan DO, Fisher RP, Espinoza FH, et al. Control of eukaryotic cell cycle progression by phosphorylation of cyclin-dependent kinases. Cancer J Sci Am. 1998;4(Suppl 1):S77--S83.PubMedGoogle Scholar
  97. 97.
    Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst. 2000;92:376–387.PubMedGoogle Scholar
  98. 98.
    Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–1512.PubMedGoogle Scholar
  99. 99.
    Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med. 1999;50:401–423.PubMedGoogle Scholar
  100. 100.
    Kerr JS, Wexler RS, Mousa SA, et al. Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res. 1999;19:959–968.PubMedGoogle Scholar
  101. 101.
    Patel V, Senderowicz AM, Pinto D Jr, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest. 1998;102:1674–1681.PubMedGoogle Scholar
  102. 102.
    Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 1998;16:2986–2999.PubMedGoogle Scholar
  103. 103.
    Tan AR, Headlee D, Messmann R, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol. 2002;20:4074–4082.PubMedGoogle Scholar
  104. 104.
    Bunch RT, Eastman A. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ. 1997;8:779–788.PubMedGoogle Scholar
  105. 105.
    Husain A, Yan XJ, Rosales N, Aghajanian C, Schwartz GK, Spriggs DR. UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II) independent of p53 status. Clin Cancer Res. 1997;3:2089–2097.PubMedGoogle Scholar
  106. 106.
    Welch S, Hirte HW, Carey MS, et al. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol. 2007;106:305–310.PubMedGoogle Scholar
  107. 107.
    de la Lastra CA, Villegas I, Sanchez-Fidalgo S. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications. Curr Pharm Des. 2007;13:933–962.PubMedGoogle Scholar
  108. 108.
    McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: an issue of potency. Cancer Biol Ther. 2005;4:934–936.PubMedGoogle Scholar
  109. 109.
    Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917.PubMedGoogle Scholar
  110. 110.
    Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–921.PubMedGoogle Scholar
  111. 111.
    Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 2004;96:56–67.PubMedGoogle Scholar
  112. 112.
    Plummer ER. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol. 2006;6:364–368.PubMedGoogle Scholar
  113. 113.
    Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res. 2005;52:25–33.PubMedGoogle Scholar
  114. 114.
    Plummer ER, Calvert H. Targeting poly(ADP-ribose) polymerase: a two-armed strategy for cancer therapy. Clin Cancer Res. 2007;13:6252–6256.PubMedGoogle Scholar
  115. 115.
    Azzabi A, Hughes AN, Calvert PM, et al. Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations. Br J Cancer. 2005;92:1006–1012.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyUniformed Services University of the Health SciencesBethesdaUSA
  2. 2.Christina Annunziata Center for Cancer Research, National Cancer InstituteAssociate Clinical Investigator, Medical Oncology BranchBethesdaUSA
  3. 3.Harvard Medical School, DirectorGynecologic Cancer Research Program, Harvard Cancer Center, Director, Gynecologic Medical Oncology, Yawkey 9, Massachusetts General HospitalBostonUSA

Personalised recommendations